Home › Trial NCT06613165
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
- Trial IDNCT06613165
- StatusRecruiting
- PhaseN/A
- Study typeObservational
- SponsorXijing Hospital
- Enrollment100
- Start date2025-01-01
- ConditionsImmune-related Adverse Event · Neoadjuvant Therapy · dMMR Colorectal Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.